NIV and

immunocompromised

patients

The third group of the four for which there is compelling evidence for the benefit of noninvasive ventilation includes immunocompromised patients who develop acute respiratory failure (ARF) and need respiratory support. Invasive ventilation is hazardous for patients with impaired immune function due to the high risk of ventilator-associated pneumonia.¹

 

A study by Antonelli in which 40 patients who had received an organ transplant and developed acute hypoxemic respiratory failure were randomized to either standard therapy (including antibiotic, antifungal or antiviral therapy with oxygen and physiotherapy) or NIV and standard therapy. Eighty percent of patients avoided intubation in the NIV group, whereas 70 percent of patients were intubated in the standard care group. Worth noting is that 6 of the 18 patients who were intubated developed VAP and died.²

 

The use of NIV to avoid endotracheal intubation to reduce the risk of ventilation associated infections is widely documented. In the article ‘Non-invasive ventilation in immunocompromised patients by Dr. Conti G, Costa R, and Antonelli M, and ‘Noninvasive ventilation for the immunocompromised patient: always appropriate?’ by Bello G, De Pascale G, Antonelli M., it is suggested that NIV is associated with shorter periods of ventilatory assistance and ICU stays, less infectious complications, and lower ICU and hospital mortality compared with invasive mechanical ventilation. This translates to lower hospitalization costs due to shorter periods of hospitalization and medication treatment.

Sign up

 

Receive updates about NIV's proven benefits for patient outcomes.

 

Sign up

Side note

Despite several studies suggesting the advantage of using NIV in immunocompromised patients, it is also stated that it may not be suitable for all immunocompromised related diseases. According to current evidence, the use of NIV is supported as the first-line treatment for managing mild and moderate ARF in immunocompromised patients.³

Video

immuno-compromised-patients

Related articles

copd

NIV in treating exacerbations of COPD

 

Strong evidence supports that NIV reduces intubation rate and mortality in patients with pulmonary edema from heart failure. Patients in ARF due to congestive heart failure are the second group of patients for which there is strong evidence to support the application of noninvasive ventilation. There are multiple randomized, controlled studies showing that NIV reduces...

 

Read more

extubation

NIV in the post-extubation period

 

NIV is used post-extubation period to reduce the length of invasive ventilation and prevent extubation failure. NIV can also play a role after invasive mechanical ventilation in the post-extubation periods. The main reasons to use NIV after extubations are to reduce the length of invasive ventilation and to prevent extubation failure. However, NIV can also...

 

Read more

pulmonary-edema

NIV in treating pulmonary edema

 

Strong evidence supports that NIV reduces intubation rate and mortality in patients with pulmonary edema from heart failure. Patients in ARF due to congestive heart failure are the second group of patients for which there is strong evidence to support the application of noninvasive ventilation. There are multiple randomized, controlled studies showing that NIV reduces...

 

Read more

thin-stripe-line-mk4

thinkNIV

 

Despite its proven benefits to improve patient comfort and reduce mortality and also costs, noninvasive ventilation (NIV) is still underutilized at many hospitals. This website is designed to promote the usage of NIV by sharing the many situations in which NIV improves patients’ outcomes as well as to inform about the factors which are important in order to perform successful NIV.

Copyright 2013. All Right Reserved